- Home
- CHRS
as 11-20-2025 3:41pm EST
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 186.0M | IPO Year: | 2014 |
| Target Price: | $4.51 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.71 - $2.43 | Next Earning Date: | 11-06-2025 |
| Revenue: | $277,728,000 | Revenue Growth: | 152.07% |
| Revenue Growth (this year): | -82.32% | Revenue Growth (next year): | 109.48% |
Latest Coherus BioSciences Inc. News
CHRS Breaking Stock News: Dive into CHRS Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
GuruFocus.com
14 days ago
Coherus Oncology Inc (CHRS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Zacks
14 days ago
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
14 days ago
Coherus Oncology: Q3 Earnings Snapshot
GlobeNewswire
14 days ago
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
14 days ago
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
Simply Wall St.
17 days ago
3 Penny Stocks With Market Caps Over $80M To Consider
Simply Wall St.
18 days ago
Coherus Oncology's (NASDAQ:CHRS) investors will be pleased with their solid 132% return over the last year
Compare CHRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CHRS Coherus BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.